Vyondys 53

success failure signposts

Pharma

NS Pharma's Duchenne drug Viltepso flunks confirmatory trial

NS Pharma's Viltepso has flunked a confirmatory trial, placing its 2020 accelerated FDA approval in jeopardy.

Kevin Dunleavy May 28, 2024 11:54am

priority review voucher

Sarepta pawns off PRV for $102M to unidentified buyer

Jul 6, 2023 8:10am

Wheelchair

NS Pharma Duchenne drug wins speedy FDA nod to challenge Sarepta

Aug 13, 2020 11:34am